The US FDA has also approved the combination of bevacizumab and atezolizumab (PD-L1 inhibitor) as first-line therapy for patients with unresectable HCC, heralding the great potential of ICIs for treatment of HCC [31]. Here, CD274 is linked to hepatocellular carcinoma.